Radiotheranostics in oncology: current challenges and emerging opportunities
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …
assessment in patients with cancer; however, as clinicians increasingly seek to …
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent …
M Passhak, MG McNamara, RA Hubner… - Best Practice & …, 2023 - Elsevier
Gastro-enterohepatic neuroendocrine tumours (GEP-NETs) represent a rare and highly
heterogeneous entity with increasing incidence. Based on the results obtained from several …
heterogeneous entity with increasing incidence. Based on the results obtained from several …
PET/CT and PET/MRI in neuroendocrine neoplasms
Advanced molecular imaging has come to play an integral role in the management of gastro-
entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Somatostatin receptor (SSTR) …
entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Somatostatin receptor (SSTR) …
Gastroenteropancreatic neuroendocrine tumor diagnosis: DOTATATE PET/CT
A Kandathil, RM Subramaniam - PET clinics, 2023 - pet.theclinics.com
Neuroendocrine neoplasms (NENs) arise in secretory cells of the diffuse neuroendocrine
system, most commonly involving the gastrointestinal (GI) tract and pancreas. NENs include …
system, most commonly involving the gastrointestinal (GI) tract and pancreas. NENs include …
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study
Purpose To correlate somatostatin receptor (SSTR) and proliferative activity profile (SSTR2,
SSTR5, Ki-67) at immunohistochemistry (IHC) with SSTR-PET/CT imaging features in a …
SSTR5, Ki-67) at immunohistochemistry (IHC) with SSTR-PET/CT imaging features in a …
RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer
G Han, E Hwang, F Lin, R Clift, D Kim, M Guest… - Molecular Cancer …, 2023 - AACR
Overexpression of somatostatin receptors (SSTR), particularly SSTR2, is found in
gastroenteropancreatic neuroendocrine tumors (GEP-NET), and subsets of other solid …
gastroenteropancreatic neuroendocrine tumors (GEP-NET), and subsets of other solid …
Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms
Neuroendocrine neoplasia (NEN) is an umbrella term that includes a widely heterogeneous
disease group including well-differentiated neuroendocrine tumours (NETs), and aggressive …
disease group including well-differentiated neuroendocrine tumours (NETs), and aggressive …
[111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
BA Nock, P Kanellopoulos, ES Moon, M Rouchota… - Pharmaceutics, 2023 - mdpi.com
Aiming to expand the application of the SST2R-antagonist LM4 (DPhe-c [DCys-4Pal-DAph
(Cbm)-Lys-Thr-Cys]-DTyr-NH2) beyond [68Ga] Ga-DATA5m-LM4 PET/CT (DATA5m,(6 …
(Cbm)-Lys-Thr-Cys]-DTyr-NH2) beyond [68Ga] Ga-DATA5m-LM4 PET/CT (DATA5m,(6 …
[HTML][HTML] Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments
S Richter, C Steenblock, A Fischer, S Lemm… - Theranostics, 2024 - ncbi.nlm.nih.gov
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …
[HTML][HTML] Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
J Martinez, K Subramanian, SH Castellanos… - Translational …, 2023 - Elsevier
The clinical utility of gallium 68 (68 Ga)-PSMA PET for the diagnosis and management of
prostate cancer is driven in part by radioisotope availability and production costs. This study …
prostate cancer is driven in part by radioisotope availability and production costs. This study …